PROTECHT Score Calculator
Cancer-Associated VTE Risk Assessment
Enter the patient's pre-chemotherapy characteristics and planned chemotherapy regimen. The score updates automatically.
Use the score alongside clinical assessment and bleeding risk when considering thromboprophylaxis.
The commonly used PROTECHT threshold identifies a score ≥3 as high risk. Risk scores have imperfect discrimination and should not independently determine anticoagulant prophylaxis.
About the PROTECHT score
The PROTECHT score is a modified Khorana risk assessment model for chemotherapy-associated venous thromboembolism (VTE) in ambulatory patients with cancer. It retains the five Khorana components and adds one point for platinum-based chemotherapy and one point for gemcitabine chemotherapy.
Scoring criteria
| Variable | Criterion | Points |
|---|---|---|
| Pancreas or stomach cancer | Very-high-risk tumor site | +2 |
| Lung, lymphoma, gynecologic, bladder, or testicular cancer | High-risk tumor site | +1 |
| Platelet count | ≥350 × 10⁹/L before chemotherapy | +1 |
| Hemoglobin / ESA | Hemoglobin <10 g/dL or erythropoiesis-stimulating agent use | +1 |
| White blood cell count | >11 × 10⁹/L before chemotherapy | +1 |
| BMI | ≥35 kg/m² | +1 |
| Platinum-based chemotherapy | Planned or received | +1 |
| Gemcitabine chemotherapy | Planned or received | +1 |
Interpretation
A score of 3 or more is commonly used as the high-risk threshold in research and risk-stratification practice. A score below 3 does not exclude VTE risk. The score is a risk assessment aid, not a diagnostic test for existing thrombosis.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.